Valsartan improves fibrinolytic balance in atherosclerotic rabbits

Journal of Hypertension

Volumn 20, Issue 2, 2002, Pages 303-310

  Oubiña, M Pilar ^a   De las Heras, Natalia ^a   Vázquez Pérez, Sandra ^a   Cediel, Eva ^a   Sanz Rosa, David ^a   Ruilope, Luis M ^a   Cachofeiro, Victoria ^a   Lahera, Vicente ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Angiotensin II; AT1 receptor antagonism; Atherosclerosis; Coagulation; Endothelial function; Fibrinolysis; Hypercholesterolemia

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYSIS; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SYSTOLIC BLOOD PRESSURE; THROMBIN TIME; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0036464211     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200202000-00021     Document Type: Article

References (50)

1. Endothelial function: General considerations
2. Endothelium-mediated coronary blood flow modulation in humans: Effects of age, atherosclerosis hyper-cholesterolemia and hypertension
3. Atherosclerosis: Basic mechanisms. Oxidation, inflammation and genetics
4. Inactivation of endothelial-derived relaxing factor by oxidized lipoproteins
5. Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits
6. The protective role of atorvastatin on function, structure and ultrastructure in the aorta of dyslipidemic rabbits
7. Thrombosis and atherosclerosis
8. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
9. Plasminogen activator inhibitor type 1 synthesis and mRNA expression in Hep G2 cells are regulated by VLDL
10. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions
11. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells
12. Endothelial function as a determinant of vascular function and structure: A new therapeutic target
13. Essential hypertension: Renin and aldosterone, heart attack and stroke
14. Angiotensin II regulates the expression of plasminiogen activator inhibitor-1 in cultured endothelial cells
15. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
16. Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells
17. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
18. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit
19. Baseline rest electrocardiographic abnormalities, antihypertensive treatment and mortality in the Multiple Risk Factor Intervention Trial
20. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin
21. On the role of bradykinin in secretion from vascular endothelial cells
22. AT1 receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits
23. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type receptor antagonism on plasma fibrinolytic balance in humans
24. Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis
25. Fibrin, D-dimer, haemostatic factors and peripheral arterial disease
26. D-dimer and fibrinolysis with various degrees of atherosclerosis
27. Effect of valsartan on angiotensin I-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells
28. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. Atherosclerosis risk in communities study
29. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart study
30. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
31. The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man
32. Regulation of local tissue-type plasminogen activator by endothelium-dependent and endothelium-independent agonists in human vasculature
33. Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals
34. Redox modulation of the pro-fibrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation
35. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension
36. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
37. Effect of trandolapril and Iosartan on plasma PAI-1 and fibrinogen in hypertensive post-menopausal women
38. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension
39. PAI-1, obesity, insulin resistance and risk of cardiovascular events
40. Augmentation of endothelial arterial cell expression of plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo
41. Synergistic effects of aldosterone and angiotensin II on PAI-1 expression
42. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells
43. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells
44. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II
45. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1
46. Acute renal excretory actions of Iosartan in spontaneously hypertensive rats: Role of AT2 receptors, prostaglandins, kinins and nitric oxide
47. The potential role of nitric oxide in angiotensin II-receptor blockade
48. Bradykinin stimulates tissue plasminogen activator release in human vasculature
49. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis
50. Involvement of enhanced coagulation and fibrinolysis system in induction of atherosclerosis in hyperlipidemic rabbits fed on a high cholesterol diet